Data protection Impressum

Pharma

Top Stories Western Switzerland

Business environment

Top Stories from Western Switzerland (October-December 2023)

19 December 2023

Cytiva’s recent move underlines Western Switzerland’s Health Valley region's growing significance as a hub for healthcare technology.

Cytiva’s strategic expansion in Western Switzerland’s Health Valley

11 December 2023

Siegfried’s Evionnaz site currently employs 380 professionals and is in the process of constructing a new R&D building, which is set to double the company's development capacity and create around 40 new jobs.

Siegfried, a Swiss leader taking innovations to industrial scale for the pharmaceutical industry

4 December 2023

LAGOSTA specializes in the sustainable farming of the European spiny lobster, converting byproducts in unique highly valuable products and setting up a series of ecological programs.

Vaud-based LAGOSTA and global giant Merck collaborate on chitosan distribution

2 November 2023

Located in Lonza's Visp industry park, Bacthera's MC4a Center of Excellence covers 12,000 square meters, featuring three manufacturing floors with one dedicated to SER-109 production.

Bacthera’s Visp plant aims to revolutionize microbiome-based treatments

30 October 2023

Established in the canton of Valais since 1989, Debiopharm is building a full-scale research and innovation campus in Martigny.

Debiopharm invests CHF 30 million in Valais amidst workforce surge

26 October 2023

On 19 September 2023, Mecaplast Swiss, a 50-year veteran in plastic injection with a medtech specialization, welcomed 50 Swiss Health Valley members on the occasion of BioAlps’ 4à6 event.

Mecaplast Swiss, 50 years of innovation in the canton of Fribourg

24 October 2023

Valsynthèse’s name originates from the high-energy value of the chemical reactions involved, necessitating a special skill set for manipulation.

Valsynthèse, 40 years of innovation in the canton of Valais

23 October 2023

The latest collaboration complements Vaxcyte’s strategy to commence the initial commercial launch of VAX-24, a vaccine that targets the prevention of invasive pneumococcal disease (IPD).

Lonza expands to manufacture Vaxcyte’s pneumococcal conjugate vaccine

17 October 2023

CDMOs play a crucial role in the pharmaceutical sector, serving as key partners in the drug development and production process.

Siegfried and Lonza secure top positions in global pharmaceutical outsourcing rankings

16 October 2023

1 … 3 4 5 6 7 8 9 10 11 … 14